Ron Squarer Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Ron Squarer.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Ron Squarer. Ron Squarer is CEO in ARRAY BIOPHARMA INC ($ARRY) and Chief Commercial Officer in HOSPIRA INC ($HSP) and SVP, Global Marketing in HOSPIRA INC ($HSP) and Director in Retrophin, Inc. ($RTRX) and Director in Deciphera Pharmaceuticals, Inc. ($DCPH).
Latest Insider Trading Transactions of Ron Squarer
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ARRY, DCPH, HSP, RTRX
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 18 2021 | RTRX | Travere Therapeuti ... | Squarer Ron | Director | Option Exercise | A | 18.27 | 9,000 | 164,430 | 9,000 | |
| May 18 2021 | RTRX | Travere Therapeuti ... | Squarer Ron | Director | Grant | A | 0.00 | 3,000 | 0 | 14,875 | 11.9 K to 14.9 K (+25.26 %) |
| Jan 20 2021 | DCPH | Deciphera Pharmace ... | Squarer Ron | Director | Option Exercise | A | 50.07 | 1,563 | 78,259 | 1,563 | |
| Jul 17 2020 | DCPH | Deciphera Pharmace ... | Squarer Ron | Director | Option Exercise | A | 53.41 | 723 | 38,615 | 723 | |
| Jun 12 2020 | DCPH | Deciphera Pharmace ... | Squarer Ron | Director | Option Exercise | A | 56.46 | 12,000 | 677,520 | 12,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Option Exercise | A | 15.43 | 9,000 | 138,870 | 9,000 | |
| May 19 2020 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Grant | A | 0.00 | 3,000 | 0 | 11,875 | 8.9 K to 11.9 K (+33.80 %) |
| Dec 06 2019 | DCPH | Deciphera Pharmace ... | Squarer Ron | Director | Option Exercise | A | 51.85 | 24,000 | 1,244,400 | 24,000 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | D | 15.97 | 678,750 | 10,839,638 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | D | 10.92 | 600,000 | 6,552,000 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | D | 8.79 | 421,875 | 3,708,281 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | D | 3.00 | 453,750 | 1,361,250 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | D | 7.30 | 113,438 | 828,097 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | D | 4.63 | 345,312 | 1,598,795 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | D | 3.61 | 545,820 | 1,970,410 | 0 | |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | D | 0.00 | 442,190 | 0 | 0 | 442.2 K to 0 (-100.00 %) |
| Jul 30 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | D | 48.00 | 259,891 | 12,474,768 | 442,190 | 702.1 K to 442.2 K (-37.02 %) |
| May 10 2019 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Option Exercise | A | 17.94 | 8,000 | 143,520 | 8,000 | |
| May 10 2019 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Grant | A | 0.00 | 2,000 | 0 | 8,875 | 6.9 K to 8.9 K (+29.09 %) |
| Apr 03 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 18,906 | 0 | 18,907 | |
| Apr 03 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 18,907 | 0 | 0 | |
| Apr 03 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 24.60 | 16,631 | 409,123 | 259,891 | 276.5 K to 259.9 K (-6.01 %) |
| Apr 03 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 37,813 | 0 | 276,522 | 238.7 K to 276.5 K (+15.84 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 3.61 | 110,000 | 397,100 | 545,820 | |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 21.64 | 110,000 | 2,380,015 | 238,709 | 348.7 K to 238.7 K (-31.54 %) |
| Feb 08 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 3.61 | 110,000 | 397,100 | 348,709 | 238.7 K to 348.7 K (+46.08 %) |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 7.30 | 113,438 | 828,097 | 113,438 | |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 3.61 | 100,000 | 361,000 | 655,820 | |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 18.53 | 113,438 | 2,101,541 | 238,709 | 352.1 K to 238.7 K (-32.21 %) |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 7.30 | 113,438 | 828,097 | 352,147 | 238.7 K to 352.1 K (+47.52 %) |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 18.25 | 100,000 | 1,825,370 | 238,709 | 338.7 K to 238.7 K (-29.52 %) |
| Feb 01 2019 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 3.61 | 100,000 | 361,000 | 338,709 | 238.7 K to 338.7 K (+41.89 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 25,000 | 0 | 75,000 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 23,437 | 0 | 46,876 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 678,750 | 0 | 678,750 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 113,125 | 0 | 113,125 | |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 15.97 | 21,303 | 340,209 | 238,709 | 260 K to 238.7 K (-8.19 %) |
| Dec 18 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 48,437 | 0 | 260,012 | 211.6 K to 260 K (+22.89 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 8.79 | 140,625 | 1,236,094 | 421,875 | |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 77,881 | 0 | 0 | |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 18.03 | 140,625 | 2,535,469 | 211,575 | 352.2 K to 211.6 K (-39.93 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 8.79 | 140,625 | 1,236,094 | 352,200 | 211.6 K to 352.2 K (+66.47 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 17.74 | 43,628 | 773,961 | 211,575 | 255.2 K to 211.6 K (-17.10 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 18.50 | 34,253 | 633,681 | 255,203 | 289.5 K to 255.2 K (-11.83 %) |
| Jun 29 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 77,881 | 0 | 289,456 | 211.6 K to 289.5 K (+36.81 %) |
| May 11 2018 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Option Exercise | A | 26.52 | 10,000 | 265,200 | 10,000 | |
| May 11 2018 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Grant | A | 0.00 | 2,500 | 0 | 6,875 | 4.4 K to 6.9 K (+57.14 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 18,906 | 0 | 37,813 | |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 16.32 | 16,605 | 270,994 | 211,575 | 228.2 K to 211.6 K (-7.28 %) |
| Apr 03 2018 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 18,906 | 0 | 228,180 | 209.3 K to 228.2 K (+9.03 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 5.94 | 333,165 | 1,979,000 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 4.63 | 79,688 | 368,955 | 345,312 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 3.61 | 133,380 | 481,502 | 755,820 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 3.61 | 110,800 | 399,988 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 5.94 | 16,835 | 100,000 | 0 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 7.30 | 226,874 | 1,656,180 | 226,876 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 10.92 | 600,000 | 6,552,000 | 600,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 100,000 | 0 | 100,000 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 23,437 | 0 | 70,313 | |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 10.93 | 546,233 | 5,970,327 | 209,274 | 755.5 K to 209.3 K (-72.30 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 5.94 | 333,165 | 1,979,000 | 755,507 | 422.3 K to 755.5 K (+78.89 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 4.63 | 79,688 | 368,955 | 422,342 | 342.7 K to 422.3 K (+23.26 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 3.61 | 133,380 | 481,502 | 342,654 | 209.3 K to 342.7 K (+63.73 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 10.73 | 273,438 | 2,933,990 | 209,274 | 482.7 K to 209.3 K (-56.65 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 3.61 | 110,800 | 399,988 | 482,712 | 371.9 K to 482.7 K (+29.79 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 5.94 | 16,835 | 100,000 | 371,912 | 355.1 K to 371.9 K (+4.74 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 7.30 | 226,874 | 1,656,180 | 355,077 | 128.2 K to 355.1 K (+176.96 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 10.92 | 10,917 | 119,214 | 128,203 | 139.1 K to 128.2 K (-7.85 %) |
| Dec 19 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 23,437 | 0 | 139,120 | 115.7 K to 139.1 K (+20.26 %) |
| Apr 12 2017 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Option Exercise | A | 18.07 | 17,500 | 316,225 | 17,500 | |
| Apr 12 2017 | RTRX | Retrophin, Inc. | Squarer Ron | Director | Grant | A | 0.00 | 4,375 | 0 | 4,375 | 0 to 4.4 K |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 18,906 | 0 | 56,719 | |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 8.94 | 12,042 | 107,655 | 114,327 | 126.4 K to 114.3 K (-9.53 %) |
| Apr 04 2017 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 0.00 | 18,906 | 0 | 126,369 | 107.5 K to 126.4 K (+17.59 %) |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 8.79 | 562,500 | 4,944,375 | 562,500 | |
| Dec 29 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 93,750 | 0 | 93,750 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 3.00 | 453,750 | 1,361,250 | 453,750 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 0.00 | 75,625 | 0 | 75,625 | |
| Apr 05 2016 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 3.00 | 5,878 | 17,634 | 107,463 | 113.3 K to 107.5 K (-5.19 %) |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | A | 7.30 | 453,750 | 3,312,375 | 453,750 | |
| Apr 03 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Grant | A | 0.00 | 75,625 | 0 | 108,166 | 32.5 K to 108.2 K (+232.40 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Option Exercise | M | 0.00 | 77,881 | 0 | 77,881 | |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Sell | S | 8.25 | 40,000 | 330,000 | 12,927 | 52.9 K to 12.9 K (-75.58 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Payment of Exercise | F | 7.96 | 24,954 | 198,634 | 52,927 | 77.9 K to 52.9 K (-32.04 %) |
| Mar 04 2015 | ARRY | ARRAY BIOPHARMA IN ... | Squarer Ron | CEO | Buy | M | 7.96 | 77,881 | 619,933 | 77,881 | 0 to 77.9 K |
| Feb 28 2011 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Option Exercise | M | 0.00 | 1,685 | 0 | 0 | |
| Feb 28 2011 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Option Exercise | A | 0.00 | 5,519 | 0 | 11,038 | |
| Feb 28 2011 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Option Exercise | A | 52.61 | 26,025 | 1,369,175 | 26,025 | |
| Feb 28 2011 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Payment of Exercise | F | 52.46 | 2,406 | 126,219 | 5,594 | 8 K to 5.6 K (-30.07 %) |
| Feb 28 2011 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Grant | A | 0.00 | 6,315 | 0 | 8,000 | 1.7 K to 8 K (+374.78 %) |
| Feb 28 2011 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Buy | M | 0.00 | 1,685 | 0 | 1,685 | 0 to 1.7 K |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Option Exercise | M | 43.18 | 7,175 | 309,817 | 6,667 | |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Option Exercise | M | 43.18 | 6,158 | 265,902 | 13,842 | |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Option Exercise | M | 22.15 | 25,342 | 561,325 | 50,683 | |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Sell | S | 58.00 | 7,175 | 416,150 | 8,000 | 15.2 K to 8 K (-47.28 %) |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Buy | M | 43.18 | 7,175 | 309,817 | 15,175 | 8 K to 15.2 K (+89.69 %) |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Sell | S | 58.00 | 23,500 | 1,363,000 | 8,000 | 31.5 K to 8 K (-74.60 %) |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Buy | M | 43.18 | 6,158 | 265,902 | 31,500 | 25.3 K to 31.5 K (+24.30 %) |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Buy | M | 22.15 | 25,342 | 561,325 | 25,342 | 0 to 25.3 K |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Gift | G | 0.00 | 6,878 | 0 | 0 | 6.9 K to 0 (-100.00 %) |
| Jul 07 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Gift | G | 0.00 | 6,878 | 0 | 9,878 | 3 K to 9.9 K (+229.27 %) |
| Apr 01 2010 | HSP | HOSPIRA INC | Squarer Ron | Chief Commercial Of ... | Payment of Exercise | F | 56.86 | 3,122 | 177,517 | 6,878 | 10 K to 6.9 K (-31.22 %) |
| Feb 16 2010 | HSP | HOSPIRA INC | Squarer Ron | SVP, Global Marketi ... | Option Exercise | A | 0.00 | 6,519 | 0 | 7,204 | |
| Feb 16 2010 | HSP | HOSPIRA INC | Squarer Ron | SVP, Global Marketi ... | Option Exercise | A | 49.64 | 50,676 | 2,515,557 | 50,676 | |
| Mar 09 2009 | HSP | HOSPIRA INC | Squarer Ron | SVP, Global Marketi ... | Option Exercise | A | 0.00 | 685 | 0 | 685 | |
| Mar 09 2009 | HSP | HOSPIRA INC | Squarer Ron | SVP, Global Marketi ... | Option Exercise | A | 22.15 | 76,025 | 1,683,954 | 76,025 | |
| Feb 26 2009 | HSP | HOSPIRA INC | Squarer Ron | SVP, Global Marketi ... | Buy | P | 24.80 | 3,000 | 74,400 | 3,000 | 0 to 3 K |
Page: 1